N 8.02(6)(6) “Health care professional” has the meaning given under s. 180.1901 (1m), Stats.

N 8.02(6m)(6m) “One contact hour” means a period of attendance in a continuing education program of at least 50 minutes.

N 8.02(7)(7) “Patient health care record” has the meaning given under s. 146.81 (4), Stats.

N 8.03N 8.03 Certification as an advanced practice nurse prescriber. An applicant for initial certification as an advanced practice nurse prescriber shall be granted a certificate by the board if the applicant complies with all of the following:

N 8.03(1)(1) Submits an application form and the fee under s. 440.05 (1), Stats.

N 8.03(1m)(1m) Provides evidence of holding a current license to practice as a professional nurse in this state or a current license to practice professional nursing in another state which has adopted the nurse licensure compact.

N 8.03(2)(2) Provides evidence of current certification by a national certifying body approved by the board as a nurse practitioner, certified nurse-midwife, certified registered nurse anesthetist or clinical nurse specialist.

N 8.03(3)(3) Provides evidence of a master’s or doctoral degree in nursing or a related health field granted by a college or university accredited by a regional accrediting organization approved by the Council for Higher Education Accreditation. This subsection does not apply to those who received national certification as a nurse practitioner, certified nurse-midwife, certified registered nurse anesthetist or clinical nurse specialist before July 1, 1998.

N 8.03(4)(4) Provides evidence of completion of 45 contact hours in clinical pharmacology or therapeutics within 5 years preceding the application for a certificate.

N 8.03(5)(5) Provides evidence of passing a jurisprudence examination for advanced practice nurse prescribers.

N 8.03 HistoryHistory: Cr. Register, February, 1995, No. 470, eff. 3-1-95; CR 01-046: am. (1), Register October 2001 No. 550, eff. 11-1-01; CR 16-020: am. (intro.), renum. (1) to (1m) and am., cr. (1), am. (2) to (5) Register September 2016 No. 729, eff. 10-1-16.

N 8.045N 8.045 Renewal. A person holding an advanced practice nurse prescriber certificate may renew the certificate by doing all of the following:

N 8.045(1)(1) Pay the renewal fee as determined by the department under s. 440.03 (9) (a), Stats., the workforce survey fee, and any applicable late renewal fee.

N 8.045(2)(2) Complete the nursing workforce survey to the satisfaction of the board.

N 8.045(3)(3) Certify completion of the continuing education required under s. N 8.05.

N 8.045(4)(4) Provide evidence of current certification by a national certifying body approved by the board as a nurse practitioner, certified nurse-midwife, certified registered nurse anesthetist, or clinical nurse specialist.

N 8.045 HistoryHistory: CR 16-020: cr. Register September 2016 No. 729, eff. 10-1-16; correction in (3) made under s. 35.17, Stats., Register September 2016 No. 729; correction in (intro.) made under s. 35.17, Stats., Register October 2019 No. 766.

N 8.05(1)(1) Every advanced practice nurse prescriber shall complete 16 contact hours per biennium in clinical pharmacology or therapeutics relevant to the advanced practice nurse prescriber’s area of practice, including at least 2 contact hours in responsible prescribing of controlled substances.

N 8.05(3)(3) Every advanced practice nurse prescriber shall retain for a minimum period of 4 years, and shall make available to the board or its agent upon request, certificates of attendance issued by the program sponsor for all continuing education programs for which he or she claims credit for purposes of renewal of his or her certificate.

N 8.06(1)(1) May issue only those prescription orders appropriate to the advanced practice nurse prescriber’s areas of competence, as established by his or her education, training or experience.

N 8.06(2)(2) May not issue a prescription order for any schedule I controlled substance.

N 8.06(3)(3) May not prescribe, dispense or administer any amphetamine, sympathomimetic amine drug or compound designated as a schedule II controlled substance pursuant to the provisions of s. 961.16 (5), Stats., to or for any person except for any of the following:

N 8.06(3)(a)(a) Use as an adjunct to opioid analgesic compounds for the treatment of cancer-related pain.

N 8.06(3)(c)(c) Treatment of hyperkinesis, including attention deficit hyperactivity disorder.